DDInter740 DDInter465
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model, although further investigations are needed.
Flecainide {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dacomitinib
Flecainide {u} (Compound) causes {v} (Side Effect) Blood alkaline phosphatase increased
Blood alkaline phosphatase increased {u} (Side Effect) is caused by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dacomitinib
Flecainide {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Dexfenfluramine
Dexfenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacomitinib
Flecainide {u} (Compound) causes {v} (Side Effect) Blood alkaline phosphatase increased
Blood alkaline phosphatase increased {u} (Side Effect) is caused by {v} (Compound) Carvedilol
Carvedilol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacomitinib
Flecainide {u} (Compound) causes {v} (Side Effect) Blood alkaline phosphatase increased
Blood alkaline phosphatase increased {u} (Side Effect) is caused by {v} (Compound) Esomeprazole
Esomeprazole {u} may lead to a major life threatening interaction when taken with {v} Dacomitinib
Flecainide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Rabeprazole
Rabeprazole {u} may lead to a major life threatening interaction when taken with {v} Dacomitinib
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dacomitinib
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Risperidone
Risperidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacomitinib
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Clozapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacomitinib
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amitriptyline
Amitriptyline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacomitinib
Flecainide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Dacomitinib
Flecainide (Compound) causes Blood alkaline phosphatase increased (Side Effect) and Blood alkaline phosphatase increased (Side Effect) is caused by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Dacomitinib
Flecainide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Dexfenfluramine (Compound) and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Flecainide (Compound) causes Blood alkaline phosphatase increased (Side Effect) and Blood alkaline phosphatase increased (Side Effect) is caused by Carvedilol (Compound) and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Flecainide (Compound) causes Blood alkaline phosphatase increased (Side Effect) and Blood alkaline phosphatase increased (Side Effect) is caused by Esomeprazole (Compound) and Esomeprazole may lead to a major life threatening interaction when taken with Dacomitinib
Flecainide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Rabeprazole (Compound) and Rabeprazole may lead to a major life threatening interaction when taken with Dacomitinib
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Dacomitinib
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may lead to a major life threatening interaction when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Amitriptyline and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib